AU2016296216B2 - Peritoneal therapeutic fluid - Google Patents

Peritoneal therapeutic fluid Download PDF

Info

Publication number
AU2016296216B2
AU2016296216B2 AU2016296216A AU2016296216A AU2016296216B2 AU 2016296216 B2 AU2016296216 B2 AU 2016296216B2 AU 2016296216 A AU2016296216 A AU 2016296216A AU 2016296216 A AU2016296216 A AU 2016296216A AU 2016296216 B2 AU2016296216 B2 AU 2016296216B2
Authority
AU
Australia
Prior art keywords
peritoneal
meq
amount
enhancing agent
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016296216A
Other languages
English (en)
Other versions
AU2016296216A1 (en
Inventor
Guido Grentzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opterion Health AG
Original Assignee
Opterion Health AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health AG filed Critical Opterion Health AG
Publication of AU2016296216A1 publication Critical patent/AU2016296216A1/en
Application granted granted Critical
Publication of AU2016296216B2 publication Critical patent/AU2016296216B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
AU2016296216A 2015-07-20 2016-07-19 Peritoneal therapeutic fluid Active AU2016296216B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
EP15177544.2 2015-07-20
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (2)

Publication Number Publication Date
AU2016296216A1 AU2016296216A1 (en) 2017-12-14
AU2016296216B2 true AU2016296216B2 (en) 2019-05-02

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016296216A Active AU2016296216B2 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Country Status (23)

Country Link
US (2) US20180221303A1 (enExample)
EP (2) EP3120842A1 (enExample)
JP (1) JP6448847B2 (enExample)
KR (2) KR102266889B1 (enExample)
CN (2) CN110075307A (enExample)
AU (1) AU2016296216B2 (enExample)
BR (1) BR112018001005B1 (enExample)
CA (1) CA2990532C (enExample)
CO (1) CO2018000236A2 (enExample)
CY (1) CY1124467T1 (enExample)
DK (1) DK3324951T3 (enExample)
ES (1) ES2880796T3 (enExample)
HR (1) HRP20211319T1 (enExample)
HU (1) HUE055208T2 (enExample)
LT (1) LT3324951T (enExample)
MX (1) MX387020B (enExample)
PL (1) PL3324951T3 (enExample)
PT (1) PT3324951T (enExample)
RS (1) RS62142B1 (enExample)
RU (1) RU2718908C2 (enExample)
SI (1) SI3324951T1 (enExample)
SM (1) SMT202100428T1 (enExample)
WO (1) WO2017013120A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2009017866A1 (en) * 2007-07-31 2009-02-05 Elc Management Llc Cosmetic compositions containing resveratrol derivatives
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
US8431617B2 (en) * 2002-11-06 2013-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin
AU7879500A (en) 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
CN101296693B (zh) 2005-10-26 2012-07-04 花王株式会社 持久力提高剂
KR20110096132A (ko) * 2008-11-26 2011-08-29 리포프로틴 테크놀로지스, 인코포레이티드 레스베라트롤의 향상된 생활성 제제
EP3085365A3 (en) * 2009-01-19 2017-01-04 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
PE20150288A1 (es) * 2012-04-24 2015-02-22 Univ British Columbia Dialisato a base de polimero
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
US8431617B2 (en) * 2002-11-06 2013-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2009017866A1 (en) * 2007-07-31 2009-02-05 Elc Management Llc Cosmetic compositions containing resveratrol derivatives
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN M PEZZUTO ET AL, "Resveratrol derivatives: a patent review (2009 - 2012)", EXPERT OPINION ON THERAPEUTIC PATENTS, (2013-12-01), vol. 23, no. 12, doi:10.1517/13543776.2013.834888, ISSN 1354-3776, pages 1529 - 1546 *

Also Published As

Publication number Publication date
BR112018001005A2 (pt) 2022-09-06
CY1124467T1 (el) 2022-07-22
RU2018106122A3 (enExample) 2019-10-10
US11160766B2 (en) 2021-11-02
BR112018001005B1 (pt) 2023-11-28
ES2880796T3 (es) 2021-11-25
PL3324951T3 (pl) 2021-12-13
HUE055208T2 (hu) 2021-11-29
MX2018000336A (es) 2018-05-22
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
US20180221303A1 (en) 2018-08-09
EP3324951B1 (en) 2021-05-26
PT3324951T (pt) 2021-07-20
CN107921009A (zh) 2018-04-17
LT3324951T (lt) 2021-07-26
SI3324951T1 (sl) 2021-09-30
CA2990532A1 (en) 2017-01-26
US20200022926A1 (en) 2020-01-23
RS62142B1 (sr) 2021-08-31
WO2017013120A1 (en) 2017-01-26
AU2016296216A1 (en) 2017-12-14
HK1251176A1 (zh) 2019-01-25
DK3324951T3 (da) 2021-08-23
CN110075307A (zh) 2019-08-02
CO2018000236A2 (es) 2018-06-12
CA2990532C (en) 2020-07-14
EP3324951A1 (en) 2018-05-30
KR102266889B1 (ko) 2021-06-18
CN107921009B (zh) 2020-12-11
EP3120842A1 (en) 2017-01-25
RU2018106122A (ru) 2019-08-20
HRP20211319T1 (hr) 2021-11-26
RU2718908C2 (ru) 2020-04-15
JP6448847B2 (ja) 2019-01-09
JP2018522894A (ja) 2018-08-16
KR20180048577A (ko) 2018-05-10
KR20190025759A (ko) 2019-03-11

Similar Documents

Publication Publication Date Title
ES2370478T3 (es) Carbohidratos antiadhesivos.
US11160766B2 (en) Peritoneal therapeutic fluid
US20040180858A1 (en) Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
CN101454392A (zh) 阴离子和阳离子多糖聚合物混合物及其用途
HK40011489A (en) Peritoneal therapeutic fluid
JP2021107405A (ja) 透析用炭水化物組成物
HK1251176B (zh) 腹膜治疗液
US11185514B2 (en) Aqueous solution comprising a polyphenol
JP5646164B2 (ja) 分岐キトサン誘導体
HK1254524B (en) Aqueous solution comprising a stilbenoid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)